|
|
|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
X
|
|
INDICATIONS:
|
|
Angioedema |
|
Endometriosis |
|
Fibrocystic breast disease |
| |
|
|
SIDE EFFECTS:
|
|
Amenorrhea |
|
breakthrough bleeding |
|
decrease in breast size |
|
irregular menstrual periods |
|
spotting |
|
weight gain |
|
Peripheral edema |
|
rhabdomyolysis |
|
virilization |
|
Adenoma, hepatocellular |
|
bladder telangiectasia |
|
bleeding gums |
|
carpal tunnel syndrome |
|
cataracts |
|
cholestatic jaundice |
|
discharge from nipple |
|
eosinophilia |
|
hepatic dysfunction |
|
intracranial hypertension, benign |
|
leukocytosis |
|
pancreatitis, acute |
|
peliosis hepatis |
|
polyneuritis, acute idiopathic |
|
skin rash |
|
Stevens-Johnson syndrome |
|
thrombocytopenia |
|
thromboembolism or thrombotic and thrombophlebitic events including stroke |
|
sagittal sinus thrombosis |
|
Virilization |
|
Abnormalities in semen viscosity and volume, and in sperm count and motility |
|
testicular atrophy |
|
Hypoestrogenemia |
|
Photosensitivity |
|
Vaginitis |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
Cardiac function impairment |
|
Epilepsy |
|
Migraine headaches |
|
Renal function impairment |
|
Diabetes mellitus |
|
|
ADULT DOSE:
|
|
Endometriosis-Moderate to severe: Oral, 400 mg two times a day (beginning Day 1 of menstruation, if possible) for at least three to six months, and may be continued for nine months if necessary.
Mild: Oral, 100 to 200 mg two times a day (beginning Day 1 of menstruation, if possible) for at least three to six months, and may be continued for nine months if necessary.
Note: If symptoms recur after discontinuation of therapy, therapy may be reinstituted.
Fibrocystic breast disease-Oral, 50 to 200 mg two times a day (beginning Day 1 of menstruation, if possible) for six months or until the symptoms completely disappear, whichever comes first.
Note: If symptoms recur within one year of discontinuation of therapy, therapy may be reinstituted.
Hereditary angioedema, prophylaxis of -Oral, initially 200 mg two or three times a day until the desired initial response is obtained; then the maintenance dosage is determined by decreasing the initial dosage by 50% or less at intervals of one to three months or longer, depending on the frequency of attacks prior to treatment.
Note: Daily dosage may be increased by up to 200 mg if the condition is not controlled at lower doses.
[Primary menorrhagia]-Oral, 200 to 400 mg a day, in divided doses (beginning Day 1 of menstruation, if possible), for up to six months.
Note: If no improvement is seen after two or three cycles, therapy should be discontinued and the cause of the excess bleeding reassessed. |
|
MAXIMUM ADULT DOSE:
|
|
800 mg per day.
|
|
PEDIATRIC DOSE:
|
|
Dosage has not been established.
|
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
|
|
|
|
|
|